The United States Food and Drug Administration (FDA) has suspended Valneva SE’s license for IXCHIQ, citing four new reports of serious adverse events (SAEs) consistent with chikungunya-like illness. The suspension is effective immediately and requires Valneva to stop shipping and selling IXCHIQ in the United States. The decision to suspend IXCHIQ is based on updated VAERS data (Vaccine Adverse Event Reporting System), which now includes four additional SAEs that occurred outside the United St...